INIS
reviews
100%
patients
100%
adults
100%
spectra
100%
diseases
100%
therapy
100%
molecules
75%
monoclonal antibodies
75%
comparative evaluations
50%
management
50%
drugs
50%
safety
50%
design
25%
inclusions
25%
risks
25%
evaluation
25%
recommendations
25%
performance
25%
guidelines
25%
mortality
25%
clinical trials
25%
optics
25%
myelitis
25%
inflammation
25%
prednisone
25%
tables
25%
Medicine and Dentistry
Neuromyelitis Optica
100%
Rituximab
100%
Systematic Review
100%
Diseases
100%
Azathioprine
50%
Tocilizumab
50%
Eculizumab
50%
Satralizumab
50%
Recurrence Risk
37%
Monoclonal Antibody
37%
Expanded Disability Status Scale
37%
Adverse Event
25%
Observational Study
12%
Arm
12%
Randomized Controlled Trial
12%
Optic Neuritis
12%
Transverse Myelitis
12%
Early Diagnosis
12%
Immunosuppressive Treatment
12%
Inflammatory Disorder
12%
Randomized Clinical Trial
12%
Placebo
12%
Prednisone
12%
Bortezomib
12%
Risk-Benefit Ratio
12%
Inebilizumab
12%
Mycophenolic Acid
12%
Pharmacology, Toxicology and Pharmaceutical Science
Myelooptic Neuropathy
100%
Rituximab
100%
Diseases
100%
Azathioprine
50%
Tocilizumab
50%
Satralizumab
50%
Eculizumab
50%
Monoclonal Antibody
37%
Recurrence Risk
37%
Expanded Disability Status Scale
37%
Adverse Event
25%
Randomized Clinical Trial
12%
Observational Study
12%
Randomized Controlled Trial
12%
Mycophenolic Acid
12%
Inflammatory Disease
12%
Placebo
12%
Optic Neuritis
12%
Immunosuppressive Agent
12%
Myelitis
12%
Bortezomib
12%
Prednisone
12%
Inebilizumab
12%
Neuroscience
Neuromyelitis Optica
100%
Rituximab
100%
Eculizumab
50%
Azathioprine
50%
Satralizumab
50%
Tocilizumab
50%
Monoclonal Antibody
37%
Expanded Disability Status Scale
37%
Randomized Controlled Trial
12%
Optic Neuritis
12%
Myelitis
12%
Transverse Myelitis
12%
Placebo
12%
Immunosuppressive Drug
12%
Prednisone
12%
Bortezomib
12%
Inebilizumab
12%
Mycophenolic Acid
12%
Keyphrases
Eculizumab
50%
Satralizumab
50%
Annualized Relapse Rate
37%
Expanded Disability Status Scale
37%
Time to Relapse
25%
Nonrandomized Studies
25%
Treatment Management
12%
Multicenter Randomized Controlled Trial
12%
Recurrent Episodes
12%
Inebilizumab
12%
Multiple Outcomes
12%
Risk-benefit Ratio
12%
Myelitis
12%
Treatment Recommendations
12%
Mycophenolate
12%
Treatment Agent
12%
Devic's
12%
Time to First Relapse
12%
Bortezomib
12%
Subtle Differences
12%
Disorders Diagnosis
12%